1-(N-Boc-氨基甲基)-4-(氨基甲基)苯 | 108468-00-4

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(N-Boc-氨基甲基)-4-(氨基甲基)苯
• 中文别名: N-[4-(氨基甲基)苄基]氨基甲酸叔丁酯；1-(N-BOC-氨基甲基)-4-氨甲基苯
• 英文名称: tert-butyl 4-(aminomethyl)benzylcarbamate
• 英文别名: 1-(N-Boc-aminomethyl)-4-(aminomethyl)benzene；4-(bocaminomethyl)benzylamine；(4-aminomethyl-benzyl)-carbamic acid tert-butyl ester；tert-butyl N-[[4-(aminomethyl)phenyl]methyl]carbamate
• CAS: 108468-00-4
• 化学式: C₁₃H₂₀N₂O₂
• 分子量: 236.314
• InChiKey: NUANLVJLUYWSER-UHFFFAOYSA-N

物化性质

• 熔点：
  64-68 °C (lit.)
• 沸点：
  250 °C(lit.)
• 密度：
  1.06 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  如果按照规定使用和储存，则不会分解，没有已知危险反应。请避免与强氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将贮藏器保持密封状态，并存放在阴凉、干燥处。同时，确保工作环境具有良好的通风或排气设施。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 1-(N-Boc-aminomethyl)-4-(aminomethyl)benzene
CAS-No. : 108468-00-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C13H20N2O2
Molecular Weight : 236,31 g/mol
Component Concentration
1-(N-Boc-aminomethyl)-4-(aminomethyl) benzene
CAS-No. 108468-00-4 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 64 - 68 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(N-Boc-氨基甲基)-4-(氨基甲基)苯 在 2-双环己基膦-2',6'-二甲氧基联苯 、 tris-(dibenzylideneacetone)dipalladium(0) 、 二碘甲烷 、 硫酸 、 caesium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 、 水 为溶剂， 反应 26.5h， 生成 1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine
  参考文献：
  名称：

  Toll 样受体 7 和 8 基于咪唑喹啉的激动剂/拮抗剂对

  摘要：

  Toll 样受体 (TLR) 7 和 8 是开发用于治疗传染病、癌症和自身免疫性疾病的免疫调节药物的关键靶点。这些受体可以采用激动剂和拮抗剂结合构象，将受体信号打开或关闭以产生下游细胞因子。在这项研究中，我们检查了两种咪唑喹啉激动剂的简单异构取代对 C2-丁基的影响，并使用 TLR7 和 TLR8 报告细胞和细胞因子诱导测定评估了这些类似物的活性。结果显示C2-异丁基和C2-环丙基甲基异构体都是母体激动剂[4-氨基-1-(4-(氨基甲基)苄基)-2-丁基-7-甲氧基羰基-1的混合TLR7/8竞争性拮抗剂H-咪唑[4,5- c]喹啉]，表明二聚体受体复合物的构象对配体结合口袋的空间扰动高度敏感。这一观察结果与先前的工作一致，证明 TLR7 和 TLR8 活性与投射到受体二聚体界面处的疏水袋中的 C2-烷基取代直接相关。此处确定的激动剂/拮抗剂对的密切结构关系突出了该口袋在改变受体激动剂和拮抗

  DOI：

  10.1016/j.bmcl.2022.128548
• 作为产物：
  描述：

  4-(叠氮甲基)苯甲腈 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 作用下， 以 四氢呋喃 为溶剂， 20.0~35.0 ℃ 、310.26 kPa 条件下， 反应 28.0h， 生成 1-(N-Boc-氨基甲基)-4-(氨基甲基)苯
  参考文献：
  名称：

  Unexpected enhancement of thrombin inhibitor potency with o -aminoalkylbenzylamides in the P1 position

  摘要：

  Thrombin inhibitors incorporating o-aminoalkylbenzylamides in the P1 position were designed, synthesized and found to have enhanced potency and selectivity in several different structural classes. X-ray crystallographic analysis of compound 24 bound in the alpha-thrombin-hirugen complex provides an explanation for these unanticipated results. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00732-7
• 作为试剂：
  描述：

  Thioctic acid 在 N-羟基丁二酰亚胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 1-(N-Boc-氨基甲基)-4-(氨基甲基)苯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Light-triggered covalent assembly of gold nanoparticles in aqueous solution

  摘要：

  紫外光照射触发表面分别被邻硝基苯甲醇和苯甲胺功能化的Au NPs进行共价连接反应，从而导致Au NPs在水溶液中通过吲达唑酮键组装成各向异性的一维（1D）阵列。

  DOI：

  10.1039/c0cc03361h

文献信息

• Synthesis of short cationic antimicrobial peptidomimetics containing arginine analogues
  作者：Leonardo Baldassarre、Francesco Pinnen、Catia Cornacchia、Erika Fornasari、Luigina Cellini、Marina Baffoni、Ivana Cacciatore

  DOI：10.1002/psc.2435

  日期：2012.9

  Worldwide efforts are underway to develop new antimicrobial agents against bacterial resistance. To identify new compounds with a good antimicrobial profile, we designed and synthesized two series of small cationic antimicrobial peptidomimetics (1–8) containing unusual arginine mimetics (to introduce cationic charges) and several aromatic amino acids (bulky moieties to improve lipophilicity). Both

  全球正在努力开发新的抗细菌耐药性的抗菌剂。为了鉴定具有良好抗菌特性的新化合物，我们设计并合成了两个系列的小型阳离子抗菌肽模拟物（1-8），其中包含不同寻常的精氨酸模拟物（引入阳离子电荷）和几种芳香族氨基酸（大块部分，以改善亲脂性）。筛选了两个系列的革兰氏阳性菌（金黄色葡萄球菌和表皮葡萄球菌）和革兰氏阴性菌（大肠杆菌和肺炎克雷伯菌）代表性菌株和白色念珠菌的体外抗菌活性。。生物筛选显示，与其他合成衍生物相比，含有色氨酸残基的拟肽对金黄色葡萄球菌和表皮葡萄球菌具有最佳的抗菌活性（MIC值为7.5–50 µg / ml）。此外，小的抗菌肽模拟物衍生物2和5对被测革兰氏阴性菌和白色念珠菌具有明显的活性。。活性最高的化合物（1-2和5-6）也已针对革兰氏阳性建立的生物膜进行了测试。结果表明，这些化合物的生物膜抑制浓度值从未高达200 µg / ml。用苯丙氨酸或酪氨酸替代色氨酸导致对革兰氏阳性和革兰氏
• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012141704A1

  公开（公告）日：2012-10-18

  The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  该披露提供了公式I的化合物，包括药用可接受的盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可能对感染HCV的人有用。
• Nickel-Catalyzed Enantioselective α-Alkenylation of <i>N</i>-Sulfonyl Amines: Modular Access to Chiral α-Branched Amines
  作者：Lun Li、Yu-Cheng Liu、Hang Shi

  DOI：10.1021/jacs.1c00622

  日期：2021.3.24

  α-branched amines are common structural motifs in functional materials, pharmaceuticals, and chiral catalysts. Therefore, developing efficient methods for preparing compounds with these privileged scaffolds is an important endeavor in synthetic chemistry. Herein, we describe an atom-economical, modular method for a nickel-catalyzed enantioselective α-alkenylation of readily available linear N-sulfonyl amines

  手性α-支化胺是功能材料、药物和手性催化剂中常见的结构基序。因此，开发用于制备具有这些特权支架的化合物的有效方法是合成化学中的一项重要努力。在这里，我们描述了一种原子经济的模块化方法，用于镍催化的线性N 的对映选择性 α-烯基化-磺胺与炔烃可提供多种烯丙基胺，无需外源性氧化剂、还原剂或活化剂。该方法为构建手性α-支化胺以及α-氨基酰胺和β-氨基醇等衍生物提供了一个平台，这些衍生物可以方便地从新引入的烯烃中获得。鉴于该方法的通用性、多功能性和高原子经济性，我们预计它将具有广泛的合成效用。
• CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF
  申请人：Dynavax Technologies Corporation

  公开号：US20190151462A1

  公开（公告）日：2019-05-23

  The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.

  本公开涉及可切割的结合物（例如，基于颗粒或抗体的结合物），其中包含TLR7/8激动剂（例如，1H-咪唑[4,5-c]喹啉衍生物），包括结合连接物、可切割连接物和自消除连接物。本公开还涉及制备可切割结合物的方法，以及将其用于刺激有效的免疫反应和用于癌症治疗的用途。
• Optically pure and enriched isomers of chelating ligands and contrast agents
  申请人：Amedio C. John

  公开号：US20060155120A1

  公开（公告）日：2006-07-13

  Organic chelating ligands, organic chelating ligand precursors, and metal chelates are disclosed. Methods for synthesizing the same are also described, including methods for preparing optically-enriched or optically-pure compositions of the same.

  有机螯合配体、有机螯合配体前体和金属螯合物被披露。还描述了合成它们的方法，包括制备光学富集或光学纯度组合物的方法。